Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Mini Rev Med Chem ; 2022 May 11.
Article in English | MEDLINE | ID: covidwho-2270624

ABSTRACT

BACKGROUND: SARS-CoV and SARS-CoV-2 are extremely infective and frequently cause severe respiratory issues (acute respiratory syndrome). These emerging viruses represent huge challenges to worldwide health. Reliable and systematic examination of SARS-CoV and COVID-19 will assist in identifying infectious persons accurately. Based on the biological, chemical, and genetic link of SARS CoV-2 towards SARS-CoV, the recurrence of different anti-SARS-CoV natural drug molecules may be beneficial in the advancement of anti COVID-19 herbal drug molecules. Here, we reviewed published literature on SAR, and molecular docking study of previously synthesized derivatives, which targeted SARS-CoV along with future prospects on SARS-CoV-2 have been reviewed. This study would assist researchers in developing newer/novel potential molecules that would target SAR-CoV-2. OBJECTIVES: The review highlights the inhibition potential of heterocyclic inhibitors for SARS-CoV and SARS-CoV-2. The structure-activity relationship of potential compounds has been discussed. EVIDENCE ACQUISITION: We carried out a thorough literature assessment employing electronic databases for scientific articles highlighting potential heterocyclic inhibitors for SARS-CoV and SARS-CoV-2, published from 2010 to 2021. We recovered 415 articles, but only 220 were involved and conversed in this manuscript. The article apprehended appropriate research considering three areas: 1) SAR activity, 2) Molecular docking, and 3) Biological activity and future prospects on SARS-CoV-2. METHODS: The potential compounds with good inhibition are discussed, and their inhibition is expressed in terms of IC50. RESULTS: Heterocyclic scaffolds reflected an extensive range of therapeutic activity and may act as an initiating idea for designing and discovering potential inhibitors for SARS-CoV and SARS-CoV-2 treatment. CONCLUSION: The points highlighted here may prove to be a vital tool for medicinal chemists working/investigating more potent and efficacious scaffolds in treating SARS-CoV and SARS-CoV-2.

2.
Postgrad Med J ; 98(1162): 633-643, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1560889

ABSTRACT

'Post-COVID-19 syndrome' refers to symptoms in the convalescent phase following initial COVID-19 infection. This term encompasses a wide array of presentation involving lungs, heart and the neuromuscular system. Pulmonary manifestations include post-COVID-19 fibrosis, which is akin to post acute respiratory distress syndrome fibrosis and may reflect the permanent damage to the lungs following an initial bout of infection. Cardiovascular system is often involved, and the presentation can be in terms of acute coronary syndrome, myocarditis and heart failure. Clinical manifestations are often varied and non-specific, which entails a detailed workup and a multidisciplinary approach. Post-COVID-19 syndrome adds to the overall disease morbidity and leads to a prolonged hospital stay, greater healthcare utilisation and loss of productivity marring the country's dwindling economy. Thus, it is imperative that post-COVID-19 syndrome be prevented and identified early followed by a prompt treatment.


Subject(s)
Acute Coronary Syndrome , COVID-19 , Myocarditis , COVID-19/complications , Fibrosis , Humans , Myocarditis/diagnosis , Myocarditis/therapy , SARS-CoV-2
3.
J Dev Behav Pediatr ; 43(1): 55-59, 2022 01 01.
Article in English | MEDLINE | ID: covidwho-1546060

ABSTRACT

ABSTRACT: Telehealth has long held promise as a way to increase access to subspecialty care for children and families, including in developmental and behavioral pediatrics (DBP). The coronavirus disease 2019 (COVID-19) pandemic necessitated rapid uptake of telehealth to continue care delivery that was facilitated by "temporary" policy changes related to the pandemic. As a result, the field of DBP has recognized telehealth as a potential model of care for performing home-based diagnostic assessments, providing medication management follow-up, and delivering therapeutic interventions for children with neurodevelopmental disorders. Telehealth has been helpful in mitigating barriers families often face when attending in-person visits (lack of transportation and child care, missed work hours, etc) but has also highlighted additional determinants of health that need to be addressed to provide equitable access to care (broadband connectivity, device access, digital literacy, access to interpretation and sign language services, etc). Anticipating the lifting of pandemic-related emergency declaration and expiration of temporary policies around telehealth, the ability to continue to deliver DBP care by telehealth is uncertain. The purpose of this policy statement is to advocate for legislation and policies that support ongoing, equitable, home-based telehealth care for patients seen by DBP providers while ensuring equitable access to DBP in general. In addition, there is a need to recognize the benefits and challenges of telehealth versus in-person care and to identify clinical scenarios that favor 1 model of care versus the other.


Subject(s)
COVID-19 , Pediatrics , Telemedicine , Humans , Pandemics , SARS-CoV-2
4.
Euroasian J Hepatogastroenterol ; 11(2): 76-80, 2021.
Article in English | MEDLINE | ID: covidwho-1524362

ABSTRACT

BACKGROUND: About 20% of COVID-19 patients can have digestive symptoms, apart from the typical chest-related symptoms, and 10% of patients may have only gastrointestinal (GI) symptoms during their entire disease course. AIM AND OBJECTIVE: The purpose of this study was to describe the spectrum of abdominal computed tomographic (CT) findings in a cohort of 15 COVID-19 patients (confirmed on reverse transcription polymerase chain reaction (RT-PCR)) who presented with various GI presentations without preceding respiratory symptoms. MATERIALS AND METHODS: A total of 93 patients with COVID-19 (confirmed on RT-PCR) who underwent CT imaging (between September 28, 2020 and March 20, 2021) in our center were retrospectively searched from the existing database. Among those, 15 patients having index presentation with abdominal symptoms and underwent CT abdomen were further evaluated. RESULTS: Biliary stasis in the form of distended gallbladder and wall thickening was the most common finding, seen in 66.7% (n = 10) patients, followed by bowel wall thickening. Small bowel and large bowel thickenings were seen in 26.7% (n = 4) and 20% (n = 3) patients, respectively. Other findings include fluid-filled colon (n = 1), mesenteric venous thrombosis (MVT) (n = 2), paper-thin bowel wall and pneumatosis (n = 1), acute pancreatitis (n = 1), and ascites (n = 2). One patient who presented with abdominal pain did not show any obvious imaging findings on CT. CONCLUSION: Patients with COVID-19 can present with initial GI symptoms preceding typical respiratory symptoms. CT imaging helps in identifying the GI involvement, to rule out alternate etiologies, and also aids in appropriate management planning. HOW TO CITE THIS ARTICLE: Patel RK, Chandel K, Mittal S, et al. Abdominal Computed Tomography Findings among COVID-19 Patients with Index Gastrointestinal Manifestations: A Preliminary Single-center Experience. Euroasian J Hepato-Gastroenterol 2021;11(2):76-80.

5.
J Dev Behav Pediatr ; 42(4): 314-321, 2021 05 01.
Article in English | MEDLINE | ID: covidwho-990835

ABSTRACT

OBJECTIVE: This study aims to describe the use of telehealth in developmental behavioral pediatric (DBP) fellowship-affiliated practices during the coronavirus disease 2019 (COVID-19) global pandemic. METHODS: An electronic survey was disseminated to all DBP fellowship-associated practice locations to determine the use of telehealth in DBP care provision, before and since the beginning of the COVID-19 pandemic. We analyzed responses using descriptive statistics. RESULTS: A total of 35 of 42 eligible practice sites responded (83% response rate). Most sites (51.4%) reported using telehealth less than once per month before the COVID-19 pandemic. Since the onset of COVID-19, 100% of programs reported conducting video-based telehealth visits multiple days per week. Most sites reported conducting evaluations and follow-up visits for attention-deficit/hyperactivity disorder, autism spectrum disorder, behavioral concerns, developmental delay, genetic disorders, and learning disability. Most sites were able to continue medication management by telehealth (>88%), offer interpreter services for families with limited English proficiency participating in telehealth visits (>90%), and incorporate trainees and interdisciplinary team members in telehealth visits (>90%). Greater variability was observed in sites' ability to collect telehealth practice evaluation measures. CONCLUSION: Most sites are providing evaluations and ongoing care for DBP conditions through telehealth. The rapid adoption of telehealth can have ramifications for the way that DBP care is delivered in the future; therefore, it is imperative to understand current practice patterns and variations to determine the best use of telehealth.


Subject(s)
COVID-19/epidemiology , Fellowships and Scholarships/methods , Pediatrics/methods , Telemedicine , Attention Deficit and Disruptive Behavior Disorders/diagnosis , Child , Child Development , Child Development Disorders, Pervasive/diagnosis , Developmental Disabilities/diagnosis , Humans , Pediatrics/education , Telemedicine/methods
6.
Monaldi Arch Chest Dis ; 90(2)2020 May 07.
Article in English | MEDLINE | ID: covidwho-216029

ABSTRACT

A novel coronavirus, SARS-CoV-2, thought to have originated from bats causes COVID-19 infection which was first reported from Wuhan, China in December 2019. This virus has a high infectivity rate and has impacted a significant chunk of the population worldwide. The spectrum of disease ranges from mild to severe with respiratory system being the most commonly affected. Cardiovascular system often gets involved in later stages of the disease with acute cardiac injury, heart failure and arrhythmias being the common complications. In addition, the presence of cardiovascular co-morbidities such as hypertension, coronary artery disease in these patients are often associated with poor prognosis. It is still not clear regarding the exact mechanism explaining cardiovascular system involvement in COVID-19. Multiple theories have been put forward however, more robust studies are required to fully elucidate the "heart and virus" link. The disease has already made its presence felt on the global stage and its impact in the developing countries is going to be profound. These nations not only have a poorly developed healthcare system but there is also a huge burden of cardiovascular diseases. As a result, COVID-19 would adversely impact the already overburdened healthcare network leading to impaired cardiovascular care delivery especially for acute coronary syndrome and heart failure patients.


Subject(s)
Cardiovascular Diseases/complications , Cardiovascular System/virology , Coronavirus Infections/complications , Pneumonia, Viral/complications , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Arrhythmias, Cardiac/virology , Betacoronavirus , COVID-19 , Cardiovascular Diseases/virology , Comorbidity , Developing Countries , Heart/virology , Heart Transplantation , Humans , Myocarditis/virology , Myocardium/pathology , Pandemics , SARS-CoV-2 , ST Elevation Myocardial Infarction/virology
SELECTION OF CITATIONS
SEARCH DETAIL